PD-128,907

PD-128,907
Identifiers
	IUPAC name (4aR,10bR)-3,4a,4,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol;
CAS Number	123594-64-9 ; 300576-59-4 (hydrochloride);
PubChem CID	5311346;
ChemSpider	23180492 ;
ChEMBL	ChEMBL94015 ;
CompTox Dashboard (EPA)	DTXSID301018037 ;
Chemical and physical data
Formula	C14H19NO3
Molar mass	249.310 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN1CCO[C@H]2[C@H]1COC3=C2C=C(C=C3)O;
	InChI InChI=1S/C14H19NO3/c1-2-5-15-9-17-7-12-11-6-10(16)3-4-14(11)18-8-13(12)15/h3-4,6,12-13,16H,2,5,7-9H2,1H3/t12-,13-/m1/s1 ; Key:ZFSOBPVEIKTNQS-CHWSQXEVSA-N ;
	(what is this?) (verify)

PD-128,907 is a drug used in scientific research which acts as a potent and selective agonist for the dopamine D₂ and D₃ receptors.^[1] It is used for studying the role of these receptors in the brain, in roles such as inhibitory autoreceptors that act to limit further dopamine release,^[2] as well as release of other neurotransmitters.^[3] In animal studies, it has been shown to reduce toxicity from cocaine overdose.^[4]^[5]

References

^ DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, et al. (January 1990). "Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers". Journal of Medicinal Chemistry. 33 (1): 445–50. doi:10.1021/jm00163a068. PMID 1967318.
^ Koeltzow TE, Xu M, Cooper DC, Hu XT, Tonegawa S, Wolf ME, White FJ (March 1998). "Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice". The Journal of Neuroscience. 18 (6): 2231–8. doi:10.1523/JNEUROSCI.18-06-02231.1998. PMC 6792939. PMID 9482807.
^ Chen G, Kittler JT, Moss SJ, Yan Z (March 2006). "Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens". The Journal of Neuroscience. 26 (9): 2513–21. doi:10.1523/JNEUROSCI.4712-05.2006. PMC 6793654. PMID 16510729.
^ Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, et al. (March 2004). "Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 957–64. doi:10.1124/jpet.103.059980. PMID 14711932.
^ Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M (September 2008). "The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors". The Journal of Pharmacology and Experimental Therapeutics. 326 (3): 930–8. doi:10.1124/jpet.108.139212. PMID 18566292.

[1] DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, et al. (January 1990). "Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers". Journal of Medicinal Chemistry. 33 (1): 445–50. doi:10.1021/jm00163a068. PMID 1967318.

[2] Koeltzow TE, Xu M, Cooper DC, Hu XT, Tonegawa S, Wolf ME, White FJ (March 1998). "Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice". The Journal of Neuroscience. 18 (6): 2231–8. doi:10.1523/JNEUROSCI.18-06-02231.1998. PMC 6792939. PMID 9482807.

[3] Chen G, Kittler JT, Moss SJ, Yan Z (March 2006). "Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens". The Journal of Neuroscience. 26 (9): 2513–21. doi:10.1523/JNEUROSCI.4712-05.2006. PMC 6793654. PMID 16510729.

[4] Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, et al. (March 2004). "Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 957–64. doi:10.1124/jpet.103.059980. PMID 14711932.

[5] Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M (September 2008). "The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors". The Journal of Pharmacology and Experimental Therapeutics. 326 (3): 930–8. doi:10.1124/jpet.108.139212. PMID 18566292.

[1]

[2]

[3]

[4]

[5]

See also

References